[HTML][HTML] High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
A Oikonomou, L Valsecchi, M Quadri, T Watrin… - Biochemical …, 2023 - Elsevier
Although a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of
patients do not respond to conventional chemotherapy and experience disease relapse. A …
patients do not respond to conventional chemotherapy and experience disease relapse. A …
The challenge of making the right choice: patient avatars in the era of cancer immunotherapies
C Kayser, A Brauer, S Susanne… - Frontiers in …, 2023 - frontiersin.org
Immunotherapies are a key therapeutic strategy to fight cancer. Diverse approaches are
used to activate tumor-directed immunity and to overcome tumor immune escape. The …
used to activate tumor-directed immunity and to overcome tumor immune escape. The …
Capturing in-vitro electro-mechanochemical signals in a label-free drug testing system for atherosclerosis
A Lincon, SK Yadav, S Das, M Mandal… - Sensors and Actuators B …, 2025 - Elsevier
Atherosclerosis begins with mild intimal dysfunction and arterial lipid accumulation,
progressing to thrombosis. Macrophage-derived foam cells are crucial to the initiation and …
progressing to thrombosis. Macrophage-derived foam cells are crucial to the initiation and …
Human immunocompetent microfluidic platform for in vitro testing in immuno-oncology applications
M Modena, C Lohasz, T Häfeli, D Hasanova, L Hölting… - 2024 - researchsquare.com
In vitro evaluation of novel therapeutic approaches often fails to reliably predict efficacy and
toxicity, especially when recapitulating conditions involving recirculating cells. Current …
toxicity, especially when recapitulating conditions involving recirculating cells. Current …